Life sciences · Journal article
Cell Death and Disease · September 24, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Genotoxic chemotherapies are central components of the treatment regimen for most cancers but are rarely curative. Drug-tolerant persister cells (DTPs) evade cell death during these treatments by accessing transient adaptive states and can contribute to cancer progression after treatment. Here, we demonstrate that cancer cells can survive genotoxic chemotherapy-induced stress by accessing a DTP state wherein stress-induced bypass of mitosis precipitates continued endocycling which promotes survival by allowing cells to evade mitotic catastrophe and cell death. Mechanistic studies indicate that persistent DNA damage signaling in endocycling persister cells triggers sustained p53-independent CDK1 inhibition by WEE1 and Myt1. Continued survival in endocycling persisters is dependent on activation of this G2 checkpoint, and disrupting WEE1 or Myt1 activity using clinical-stage small molecule inhibitors is sufficient to drive CDK1 reactivation, forcing mitotic entry, catastrophe, and cell death. Our results define endocycling DTPs as targetable mediators of cancer cell persistence after genotoxic therapy.